指南与共识乳腺癌

群体致病性变异检测对基于风险的乳腺筛查建议的影响:WISDOM研究二次分析

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.
指南 / 共识 · JAMA Oncol · 2026-01-01

该队列研究基于WISDOM试验,纳入712例携带致病性变异的女性,比较基于变异状态的实际筛查分配与仅基于临床风险模型或临床联合多基因风险评分的假设分配。结果显示大多数变异携带者按临床风险不会被推荐高危筛查,提示群体致病性变异检测可识别与临床风险因素不同的高危亚群。

要点

  • 712例携带致病性变异的女性中,仅0.9%的高外显率携带者按临床联合多基因风险获得相同高危筛查分配。
  • 40-49岁携带者中63.8%按临床联合多基因风险会被建议推迟至50岁筛查。
  • 50-74岁携带者中88.9%按临床联合多基因风险会被建议每两年一次乳腺X线筛查。

核心结论

  • 大多数乳腺癌基因致病性变异携带者按临床风险或临床联合多基因风险不会被推荐高危筛查。
  • 致病性变异检测可识别与临床风险因素及多基因风险评分不同的高危女性亚群。
  • 研究结果强调在基于风险的筛查中开展群体致病性变异检测的重要性。

研究设计与样本

  • 本研究为WISDOM研究的二次分析,采用回顾性队列数据。
  • WISDOM为全国性临床试验,比较基于风险的筛查与年度乳腺X线筛查。
  • 纳入40至74岁、在基于风险筛查中检测出致病性变异阳性的女性,共712例。
  • 数据收集时间为2016年9月至2023年2月,随访至2025年9月。

主要发现

  • 712例携带致病性变异的女性中,中位年龄53岁(IQR 46-62)。
  • 232例(33%)为高外显率变异,278例(39%)为中外显率变异,202例(28%)为CHEK2低外显率变异。
  • 基于变异状态的实际筛查分配与基于临床联合多基因风险评分的假设分配之间重叠很少。
  • 高外显率变异携带者中,仅2/232(0.9%)按临床联合多基因风险获得相同的高危筛查分配。
  • 40-49岁携带者中178/279(63.8%)按临床联合多基因风险会被建议推迟至50岁筛查;50-74岁携带者中385/433(88.9%)会被建议每两年一次乳腺X线筛查。

关键数值与推荐

  • 高外显率变异携带者被推荐高危筛查,即磁共振成像与乳腺X线每6个月交替进行。
  • 基于临床联合多基因风险的假设分配中,40-49岁部分携带者被建议推迟至50岁开始筛查。
  • 基于临床联合多基因风险的假设分配中,50-74岁部分携带者被建议每两年一次乳腺X线筛查。

临床怎么用

  • 在基于风险的乳腺癌筛查中,应考虑开展群体致病性变异检测以识别临床风险模型可能漏判的高危女性。
  • 仅依赖临床风险模型或多基因风险评分可能低估致病性变异携带者的高危筛查需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Risk-based breast cancer screening has emerged as a viable alternative to annual mammography. To guide implementation, knowledge is needed on the contribution of testing for pathogenic variants (PVs) beyond clinical risk factors and common genetic variants for population-based risk stratification. OBJECTIVE: To evaluate how many PV carriers in a risk-based breast cancer screening trial would have been recommended for high-risk screening based on clinical risk or clinical plus polygenic risk. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used retrospective data from the WISDOM Study, a national clinical trial of risk-based vs annual breast cancer screening, to compare screening assignments informed by PV status vs those based on a clinical risk model alone or a clinical risk model combined with a polygenic risk score. WISDOM participants aged 40 to 74 years who tested positive for a PV as part of risk-based screening were included. Data were collected from September 2016 to February 2023, with follow-up to September 2025. Data were analyzed from January to May 2026. MAIN OUTCOMES AND MEASURES: Concordance between actual (considering participants' PV status) and hypothetical screening assignments based on a clinical (Breast Cancer Surveillance Consortium) risk model or a clinical model plus polygenic risk score. RESULTS: Of 712 included women with a PV, the median (IQR) age was 53 (46-62) years. A total of 232 PVs (33%) were high penetrance, 278 (39%) were moderate penetrance, and 202 (28%) were CHEK2 low penetrance. There was little overlap between actual screening assignments based on PV status and hypothetical assignments based on a clinical model plus polygenic risk score. Among high-penetrance PV carriers (a group recommended high-risk screening with magnetic resonance imaging alternating with mammography every 6 months), 2 of 232 (0.9%) would have received the same screening assignment based on clinical plus polygenic risk. Overall, 178 of 279 PV carriers aged 40 to 49 years (63.8%) would have otherwise been recommended to defer screening until age 50 years based on clinical plus polygenic risk, whereas 385 of 433 carriers aged 50 to 74 years (88.9%) would have been recommended biennial mammography. Results were similar when comparing assignments based on a clinical model alone. CONCLUSIONS AND RELEVANCE: In this cohort study, most participants with PVs in breast cancer genes would not have been recommended for high-risk screening based on their clinical or clinical plus polygenic risk. PV testing therefore may identify different subsets of high-risk women than clinical risk factors and polygenic risk scores. These findings highlight the importance of population-based PV testing in risk-based screening. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02620852.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Shieh Y, Heise RS, Madlensky L, et al. Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study. JAMA Oncol. 2026. PMID: 42218736. doi:10.1001/jamaoncol.2026.2091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。